Read the Patent Cliff Before Everyone Else Does: How to Evaluate Biosimilar First-Mover Advantage
The race for biosimilar first-mover advantage is decided long before the FDA approves a single molecule. It is decided in […]
Prove It’s the Same: The $200 Billion Bioequivalence Fight Reshaping Generic Drugs
The Question That Drives a $200 Billion Market Every time a pharmacist hands a patient a generic substitute for a
Prove It’s the Same: The $200 Billion Bioequivalence Fight Reshaping Generic Drugs Read Post »
505(b)(2): The Smarter Drug Development Path
How the Hybrid Regulatory Strategy Cuts Risk, Compresses Timelines, and Unlocks Pipeline Value for Pharmaceutical Executives Why Most Drug Developers
505(b)(2): The Smarter Drug Development Path Read Post »
The IRA Price Reset: What It Actually Does to Pharma Pricing, and What Comes Next
A forward-looking analysis of the Inflation Reduction Act’s structural impact on U.S. pharmaceutical economics The Price Is Wrong: What the
The IRA Price Reset: What It Actually Does to Pharma Pricing, and What Comes Next Read Post »
When the Patent Wall Crumbles: Secondary Abandonment and the Death of Drug Evergreening
Pharmaceutical companies spend decades constructing legal fortresses around their best-selling drugs. They file dozens of secondary patents on minor formulation
When the Patent Wall Crumbles: Secondary Abandonment and the Death of Drug Evergreening Read Post »
The Strategic Playbook for Identifying and Securing Drug Patent Licensing Opportunities
Introduction: Licensing as the Lifeblood of Biopharmaceutical Innovation In biopharmaceutical innovation the drug patent licensing agreement stands as the central,
The Strategic Playbook for Identifying and Securing Drug Patent Licensing Opportunities Read Post »
Beyond the API: Mapping the Secondary Patent Thicket to Forecast Generic Entry
A practitioner’s guide for pharmaceutical analysts, generics strategists, and investors who need to know when a drug is actually off-patent.
Beyond the API: Mapping the Secondary Patent Thicket to Forecast Generic Entry Read Post »
No Patents, No Problem: The Untapped Power of Drug Repurposing
In the multi-trillion-dollar pharmaceutical industry, there’s an attic. It’s filled not with dust and forgotten relics, but with something far
No Patents, No Problem: The Untapped Power of Drug Repurposing Read Post »
Double Your Specialty Pharmacy Margins the Day Generics Launch
Day one of generic competition is the moment most specialty pharmacies dread. The brand rep stops calling. The PBM’s preferred
Double Your Specialty Pharmacy Margins the Day Generics Launch Read Post »
